Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_1
2
29%
Ph phase_2
4
57%
Ph phase_3
1
14%

Phase Distribution

2

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(4)
Terminated(3)

Detailed Status

Completed4
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 24 (57.1%)
Phase 31 (14.3%)

Trials by Status

terminated229%
withdrawn114%
completed457%

Recent Activity

0 active trials
Showing 5 of 7
terminatedphase_2

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

NCT04822701
completedphase_3

Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children

NCT02358681
withdrawnphase_2

A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2

NCT04894474
completedphase_2

Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19

NCT04568863
completedphase_1

A Study of LY3016859 in Healthy Volunteers

NCT01545583
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04822701Phase 2

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

Terminated
NCT02358681Phase 3

Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children

Completed
NCT04894474Phase 2

A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2

Withdrawn
NCT04568863Phase 2

Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19

Completed
NCT01545583Phase 1

A Study of LY3016859 in Healthy Volunteers

Completed
NCT02681861Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects

Completed
NCT01018810Phase 2

A Study for Adults With Plaque Psoriasis

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7